Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8N122
UPID:
RPTOR_HUMAN
Alternative names:
p150 target of rapamycin (TOR)-scaffold protein
Alternative UPACC:
Q8N122; B2RN36; C6KEF2; F5H7J5; Q8N4V9; Q8TB32; Q9P2P3
Background:
The Regulatory-associated protein of mTOR, also known as p150 target of rapamycin (TOR)-scaffold protein, is a pivotal component of the mTORC1 complex. This complex is a central nutrient sensor that stimulates anabolic reactions, promoting cellular growth by enhancing protein, lipid, and nucleotide synthesis. It achieves this by phosphorylating key substrates such as RPS6KB1 and EIF4EBP1. Concurrently, mTORC1 inhibits autophagy by phosphorylating ULK1, ATG13, and TFEB, thus regulating cellular catabolism.
Therapeutic significance:
Understanding the role of the Regulatory-associated protein of mTOR could open doors to potential therapeutic strategies.